With gene therapy demonstrating an enormous potential to treat a wide range of diseases, Cyagen has added a range of gene therapy services to our comprehensive research model solutions. To further support scientists making notable advancements and ultimately benefiting patients around the world, we have established an innovative One-Stop Gene Therapy Research Solutions CRO Platform.
By utilizing Cyagen’s in-depth exploration in artificial intelligence (AI) with decades of genetic engineering data, we can provide scientists with advanced gene function analysis and one-stop gene therapy comprehensive solutions, including: target screening and function research, animal model construction, design and packaging of viral vectors such as AAV, LV and ADV, as well as phenotype analysis.
Our services include CRISPR Cas9 Screening & Target Validation, Custom Mouse Model Generation, Efficient Adenovirus/Lentivirus Packaging of adeno-associated virus (AAV), Lentivirus (LV), Adenovirus (ADV), Pharmacology and Pharmacodynamics (PD) Studies, and more.
Cyagen has over 15 years’ experience as an animal research model provider, having developed various robust platforms related to gene therapy, covering a variety of rare human diseases.
Cyagen has many years of experience in virus packaging, and can provide AAV, LV, ADV and other viruses that comply with different quality standards. Our virus packaging platform has been widely used in the construction of various cell line models and in vivo studies of living animals, and have been cited and published by customers in many journals. For AAV virus packaging, we adopt a three-plasmid co-transfection method. The advanced purification process can provide customized AAV packaging services with high purity, high titer, and different serotypes. It is especially suitable for in vivo animal experiments and can meet the personalized choices of gene therapy researchers.
As an international and innovative CRO provider of research model animals, Cyagen makes the establishment of gene-edited animal models more efficient through its self-developed TurboKnockout® technology and CRISPR-Pro technology. In addition, Cyagen can provide surgical disease models and gene therapy vector model construction services.
We offer a variety of effectiveness evaluation services for our gene therapy platform, including molecular, cellular (in vitro), and animal (in vivo) phenotypic testing services. Our services span the field of gene therapy, covering multiple diseases such as those affecting neurological, cardiovascular, and cerebrovascular systems, tumors, and more. We also provide customers with a comprehensive phenotype analysis system service platform to support every research model project.
The research groups of Dr. Bin Zhou and the team of Dr. Hefeng Huang co-published an article titled "In Vivo AAV-CRISPR/Cas9-mediated Gene Editing Ameliorates Atherosclerosis in Familial Hypercholesterolemia" in the journal Circulation. In this study, researchers find that adeno-associated virus (AAV) delivers CRISPR/Cas9 to achieve low-density lipoprotein receptor (LDLR) gene correction that can partially rescue LDLR expression and effectively ameliorate atherosclerosis phenotypes in Ldlr mutant mice generated by Cyagen. This finding provides a potential therapeutic method for the treatment of familial hypercholesterolemia (FH).
With more than 15 years’ experience in genetic engineering, Cyagen offers a complete range of model generation services, including: custom genetically engineered models, ready-to-use catalog models, drug development models, colony management, and phenotype analysis - enabling researchers worldwide to create, manage, and monitor models with ease.
We look forward to hearing from you!